Show simple item record

dc.contributor.authorPalau, Patricia
dc.contributor.authorLópez, Laura
dc.contributor.authorDomínguez, Eloy
dc.contributor.authorDe la Espriella, Rafael
dc.contributor.authorCampuzano, Raquel
dc.contributor.authorCastro, Almudena
dc.contributor.authorMiñana, Gema
dc.contributor.authorFernández-Cisnal, Agustín
dc.contributor.authorSanchis, Juan
dc.contributor.authorNúñez, Julio
dc.date.accessioned2024-05-22T12:11:17Z
dc.date.available2024-05-22T12:11:17Z
dc.date.issued2024-01-15
dc.identifier.citationPalau, Patricia, et al. "Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING‐HF trial." Journal of Cachexia, Sarcopenia and Muscle (2024).ca_CA
dc.identifier.issn2190-5991
dc.identifier.issn2190-6009
dc.identifier.urihttp://hdl.handle.net/10234/207481
dc.description.abstractBackground Iron deficiency (ID) is associated with impaired functional capacity in patients with heart failure (HF), even in those with preserved ejection fraction (HFpEF). This study aimed to evaluate the effect of baseline ferrokinetics on peak oxygen consumption (peakVO2) improvement after a 12-week physical therapy programme in patients with stable HFpEF. Methods This study is a post-hoc sub-analysis of a randomized clinical trial in which 59 stable patients with HFpEF were randomized to receive a 12-week programme of inspiratory muscle training (IMT), functional electrical stimulation (FES), IMT + FES or usual care (UC) to evaluate change in peakVO2 (NCT02638961). Serum ferritin and transferrin saturation (TSAT) determinations were assessed at baseline. ID was defined as ferritin <100 ng/mL and/or TSAT <20% if ferritin was within 100–299 ng/mL. We used a linear mixed regression model to analyse between-treatment changes in peakVO2 across ferrokinetics status at 12 and 24 weeks. Results The mean age was 74 ± 9 years, and 36 (61%) had ID. The mean of peakVO2 was 9.9 ± 2.5 mL/kg/min. The median of ferritin and transferrin saturation (TSAT) was 91 (50–181) ng/mL and 23% (16–30), respectively. A total of 52 patients completed the trial (13 patients per arm). Compared with those patients on UC, patients allocated to any of the active arms showed less improvement in peak VO2 when they showed ID (P-value for interaction <0.001), lower values of ferritin (P-value for interaction <0.001), or TSAT (P-value for interaction <0.001). Conclusions Ferrokinetics status plays an essential role in modifying the aerobic capacity response to physical therapies in patients with HFpEF. Further studies are required to confirm these findings.ca_CA
dc.format.extent9 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherWiley Open Accessca_CA
dc.relation.isPartOfJournal of Cachexia, Sarcopenia and Muscle 2024; 15: 681–689ca_CA
dc.relation.urihttps://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fjcsm.13419&file=jcsm13419-sup-0001-S1.jpgca_CA
dc.rights© 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLCca_CA
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/ca_CA
dc.subjectaerobic capacityca_CA
dc.subjectheart failure with preserved ejection fractionca_CA
dc.subjectiron deficiencyca_CA
dc.subjectpeakVO2ca_CA
dc.subjectphysical therapiesca_CA
dc.titleExercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trialca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.1002/jcsm.13419
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA
project.funder.nameUnidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Instituteca_CA
project.funder.nameSpanish Clinical Research Network (SCReN)ca_CA
project.funder.nameCIBER Cardiovascularca_CA
project.funder.nameSociedad Española de Cardiología, Investigacion Clınica en Cardiologıaca_CA
oaire.awardNumberPT20/00100ca_CA
oaire.awardNumberPT17/0017/0003ca_CA
oaire.awardNumber16/11/00486ca_CA
oaire.awardNumber16/11/00403ca_CA
oaire.awardNumber16/11/00420ca_CA
oaire.awardNumberSEC 2015ca_CA
dc.subject.ods3. Salud y bienestarca_CA


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC
Except where otherwise noted, this item's license is described as © 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC